Stemler, J. Et Al. 2024. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B). INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , vol.146 .

Stemler, J., Yeghiazaryan, L., Stephan, C., Mohn, K. G., Carcas-Sansuan, A., Rodriguez, E. R., ... Molto, J.(2024). Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B). INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , vol.146.

Stemler, Jannik Et Al. "Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)," INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , vol.146, 2024

Stemler, Jannik Et Al. "Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)." INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , vol.146, 2024

Stemler, J. Et Al. (2024) . "Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)." INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , vol.146.

@article{article, author={Jannik Stemler Et Al. }, title={Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)}, journal={INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES}, year=2024}